Published in N Engl J Med on May 19, 1994
Setting the record straight in the breast-cancer trials. N Engl J Med (1994) 4.86
The sequence of the human genome. Science (2001) 101.55
A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol (1981) 10.92
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A (1985) 10.71
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A (1986) 8.48
Role of suppressor T cells in pathogenesis of common variable hypogammaglobulinaemia. Lancet (1974) 8.13
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A (1986) 6.63
Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci U S A (1987) 5.17
Molecular targets for AIDS therapy. Science (1990) 4.28
Infectious mutants of HTLV-III with changes in the 3' region and markedly reduced cytopathic effects. Science (1986) 4.17
Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma Role of suppressor cells. N Engl J Med (1975) 3.81
A pathogenic retrovirus (HTLV-III) linked to AIDS. N Engl J Med (1984) 3.41
Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science (1988) 3.01
Strategies for antiviral therapy in AIDS. Nature (1987) 2.95
Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther (1987) 2.92
In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science (1989) 2.70
Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science (1984) 2.70
Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci U S A (1989) 2.62
CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. Ann Intern Med (1991) 2.35
The Sézary syndrome: a malignant proliferation of helper T cells. J Clin Invest (1976) 2.32
Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest (1993) 2.27
Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med (1989) 2.17
NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus. Ann Intern Med (1984) 2.10
Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity. Biochem Pharmacol (1987) 2.10
Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex. Lancet (1990) 2.02
Suppressor cells in the regulation of the immune response. Prog Clin Immunol (1977) 1.99
Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro. Proc Natl Acad Sci U S A (1987) 1.96
Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc Natl Acad Sci U S A (1993) 1.92
Projections of the incidence of non-Hodgkin's lymphoma related to acquired immunodeficiency syndrome. J Natl Cancer Inst (1991) 1.91
Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report. N Engl J Med (1987) 1.88
Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther (1990) 1.87
Polyclonal B-cell activators in the study of the regulation of immunoglobulin synthesis in the human system. Adv Immunol (1982) 1.85
Studies on the mechanism of human immunodeficiency virus reverse transcriptase. Steady-state kinetics, processivity, and polynucleotide inhibition. J Biol Chem (1988) 1.82
Fc-receptors on human T lymphocytes. I. Transition of Tgamma to Tmu cells. J Immunol (1978) 1.79
Disorders of suppressor immunoregulatory cells in the pathogenesis of immunodeficiency and autoimmunity. Ann Intern Med (1978) 1.78
Functional properties of antigen-specific T cells infected by human T-cell leukemia-lymphoma virus (HTLV-I). Science (1984) 1.74
Stepwise mechanism of HIV reverse transcriptase: primer function of phosphorothioate oligodeoxynucleotide. Biochemistry (1989) 1.70
Defect in IgA secretion and in IgA specific suppressor cells in patients with selective IgA deficiency. Trans Assoc Am Physicians (1976) 1.59
Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. N Engl J Med (1983) 1.58
Initial studies on the cellular pharmacology of 2',3'-dideoxyadenosine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol (1987) 1.57
Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol (1986) 1.56
Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy. J Infect Dis (1995) 1.56
Stability of HL-A and appearance of other antigens (LIVA) at the surface of lymphoblasts grown in vitro. Haematologica (1969) 1.53
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents. J Med Chem (1987) 1.53
Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders. J Clin Pharmacol (1988) 1.51
Plasma HIV-1 viremia in HIV-1 infected individuals assessed by polymerase chain reaction. AIDS Res Hum Retroviruses (1992) 1.50
Implications of the human genome for understanding human biology and medicine. JAMA (2001) 1.47
Polyclonal immunoglobulin secretion by human B lymphocytes exposed to Epstein-Barr virus in vitro. J Immunol (1979) 1.46
The role of suppressor cells in the pathogenesis of common variable hypogammaglobulinemia and the immunodeficiency associated with myeloma. Fed Proc (1976) 1.46
The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly dependent on the cell species. Biochem Pharmacol (1988) 1.45
Association of human T-cell leukaemia/lymphoma virus with the Tac antigen marker for the human T-cell growth factor receptor. Nature (1983) 1.42
Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. Mol Pharmacol (1988) 1.38
Human T-cell leukemia-lymphoma virus (HTLV) is in T but not B lymphocytes from a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A (1982) 1.37
Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo. Lancet (1985) 1.35
The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med (1989) 1.33
Targeted therapy of human immunodeficiency virus-related disease. FASEB J (1991) 1.33
Metabolic pathways for the activation of the antiretroviral agent 2',3'-dideoxyadenosine in human lymphoid cells. J Biol Chem (1988) 1.32
Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. Ann Intern Med (1990) 1.31
Characterization of a suppressor-cell leukemia. Evidence for the requirement of an interaction of two T cells in the development of human suppressor effector cells. N Engl J Med (1978) 1.30
Metabolic heterogeneity of eosinophils from normal and hypereosinophilic patients. Blood (1981) 1.27
Acid-stable 2'-fluoro purine dideoxynucleosides as active agents against HIV. J Med Chem (1990) 1.27
Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex. Clin Pharmacol Ther (1989) 1.27
The disposition and metabolism of 2',3'-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys. Drug Metab Dispos (1988) 1.26
Synthesis of phosphorothioate analogues of oligodeoxyribonucleotides and their antiviral activity against human immunodeficiency virus (HIV). Gene (1988) 1.26
Association of the human type C retrovirus with a subset of adult T-cell cancers. Cancer Res (1983) 1.25
Differences in the interaction of HIV-1 and HIV-2 with CD4. J Acquir Immune Defic Syndr (1990) 1.24
Pharmacological inhibition of infectivity of HTLV-III in vitro. Cancer Res (1985) 1.24
Human monoclonal antibody directed against an envelope glycoprotein of human T-cell leukemia virus type I. Proc Natl Acad Sci U S A (1986) 1.24
Inhibitory activity of antibodies to human Ia-like determinants: comparison of intact and pepsin-digested antibodies. J Immunol (1983) 1.23
Inhibition of infectivity and replication of HIV-2 and SIV in helper T-cells by 2',3'-dideoxynucleosides in vitro. AIDS Res Hum Retroviruses (1988) 1.22
Disorders of B cells and helper T cells in the pathogenesis of the immunoglobulin deficiency of patients with ataxia telangiectasia. J Clin Invest (1983) 1.21
Familial chronic lymphocytic leukemia. Immunologic and cellular characterization. Ann Intern Med (1976) 1.21
The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2',3'-didehydro-2',3'-dideoxyribonucleosides: a comparison with their parental 2',3'-dideoxyribonucleosides. Mol Pharmacol (1987) 1.21
Polyclonal activation of human B lymphocytes by Nocardia water soluble mitogen (NWSM). Immunol Rev (1979) 1.19
Potent and selective anti-HTLV-III/LAV activity of 2',3'-dideoxycytidinene, the 2',3'-unsaturated derivative of 2',3'-dideoxycytidine. Biochem Biophys Res Commun (1986) 1.19
Quantitative analysis of HIV-1 proviral DNA in peripheral blood mononuclear cells from patients with AIDS or ARC: decrease of proviral DNA content following treatment with 2',3'-dideoxyinosine (ddI). AIDS Res Hum Retroviruses (1990) 1.17
Interleukin-10 suppresses human immunodeficiency virus-1 replication in vitro in cells of the monocyte/macrophage lineage. Blood (1994) 1.16
Inhibition of duck hepatitis B virus replication by 2',3'-dideoxycytidine. A potent inhibitor of reverse transcriptase. Gastroenterology (1989) 1.16
Resolution of longstanding protein-losing enteropathy in a patient with intestinal lymphangiectasia after treatment for malignant lymphoma. Gastroenterology (1981) 1.16
Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2',3'-dideoxycytidine (ddC). Muscle Nerve (1989) 1.15
Adenallene and cytallene: acyclic-nucleoside analogues that inhibit replication and cytopathic effect of human immunodeficiency virus in vitro. Proc Natl Acad Sci U S A (1988) 1.13
Suppressor T cells in the pathogenesis of hypogammaglobulinemia associated with a thymoma. Trans Assoc Am Physicians (1975) 1.13
Initial clinical experience with dideoxynucleosides as single agents and in combination therapy. Ann N Y Acad Sci (1990) 1.12
Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future. Blood (1991) 1.12
Aurintricarboxylic acid and Evans Blue represent two different classes of anionic compounds which selectively inhibit the cytopathogenicity of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus. Biochem Biophys Res Commun (1986) 1.11
Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T-cell lymphotropic virus (HTLV-III)/lymphadenopathy-associated virus (LAV). Int J Cancer (1986) 1.10
Broad spectrum antiretroviral activity of 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A (1987) 1.10
Molecular foundations of cancer: new targets for intervention. Nat Med (1995) 1.10
Participation of suppressor T cells in the immunosuppressive activity of a heteroantiserum to human Ia-like antigens (p23,30). J Exp Med (1980) 1.09
Infection of monocytes by human immunodeficiency virus type 1 blocked by inhibitors of CD4-gp120 binding, even in the presence of enhancing antibodies. J Exp Med (1990) 1.09
Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol (1986) 1.09
Generation of an HLA-restricted cytotoxic T cell line reactive against cultured tumor cells from a patient infected with human T cell leukemia/lymphoma virus. J Exp Med (1983) 1.09
X-linked hypogammaglobulinemia and isolated growth hormone deficiency. N Engl J Med (1980) 1.07
Human T-cell leukemia virus: its discovery and role in leukemogenesis and immunosuppression. Adv Intern Med (1984) 1.05
T-cell response towards HIV in infected individuals with and without zidovudine therapy, and in HIV-exposed sexual partners. AIDS (1989) 1.05
Pharmacological inhibition of in vitro infectivity of human T lymphotropic virus type I. J Clin Invest (1987) 1.05
Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol (1993) 1.03